Opdivo® (nivolumab) – Expanded indication
April 25, 2017 – The FDA approved Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous hematopoietic stem cell transplantation (HSCT).
Top